NCT06340802已完成不适用
A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 6
- 主要终点
- Treatment emergent adverse events
研究概览
简要总结
This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.
详细描述
This is the first clinical investigation with the NAO.VNS SYSTEM from Synergia Medical.
Up to 10 patients with drug resistant epilespy, who are eligible for vagus nerve stimulation, will be included in two sites.
The total duration of the study is expected to be 36 months. Study procedures are composed of (i) baseline, (ii) implantation, (iii) titration and (iv) follow-up until 24 months.
Primary objective is to evaluate safety of the NAO.VNS SYSTEM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand the Informed Consent Form (ICF) and the study procedures and provide written consent or, in case of cognitive impairment, be the legal ward of a person who is able and willing to provide written consent.
- •Subjects diagnosed with Drug Resistant Epilepsy (DRE) and candidate for VNS treatment
- •Ability of subjects or, in the case of cognitive impairment, their caregiver, to accurately count seizures and complete seizure diaries.
- •Adult subjects, age ≥
- •Willingness of subjects or, in the case of cognitive impairment, their caregiver, to charge the NAO.VNS system with the Smart Charger on a weekly basis.
- •Subjects' willingness to follow the protocol procedures. For example, subject should have a careful seizure diary completion according to standard of care to ensure 8 weeks of data available by time of implant.
- •Female subjects of childbearing age using acceptable methods of birth control (abstinence considered acceptable).
排除标准
- •Unstable medical condition likely to precipitate seizures and make it difficult to evaluate efficacy.
- •Prior cervical vagotomy.
- •Progressive neurological disease.
- •Significant cardiac or pulmonary disease under treatment.
- •History of noncompliance for seizure diary completion.
- •Prior implant with vagus nerve stimulation device.
- •Current active treatment of epilepsy with cerebellar or thalamic stimulation.
- •Prior therapeutic brain surgery for epilepsy within the last 6 months prior to NAO.VNS implantation.
- •Receiving or likely to receive short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy after implantation.
- •Currently receiving another investigational treatment.
- •Patient with Vocal Cord Palsy (VCP), including unilateral, whatever the side.
- •Diabetic patients and all patients with a known vagal neuropathy.
- •Coagulation disorder, wound healing and bleeding disorder or taking anticoagulant medication (oral anticoagulants; antiplatelets (such as aspirin, ticagrelor) are allowed).
- •Patient currently participating in another clinical investigation, without explicit consent of the Sponsor (non-interventional registries are allowed).
研究组 & 干预措施
VNS Treatment
Experimental
Vagus nerve stimulation is started 2-week after the implantation.
干预措施: VNS Treatment (Device)
结局指标
主要结局
Treatment emergent adverse events
时间窗: through 3 months of implantation
Incidence rate of NAO.VNS device-related treatment emergent adverse events (TEAE)
Procedure and/or device related adverse events
时间窗: through 30 days post implant
Incidence of procedure and/or device related adverse events
次要结局
- Device-related treatment emergent adverse events(through 6, 12, 18 & 24 months of implantation)
- Procedural Success(at implantation surgery)
- Changed in mood(at 3, 6, 12, 18 & 24 months of implantation)
- Device deficiencies(at 3, 6, 12, 18 and 24 months of implantation)
- Change in seizure severity(at 3, 6, 12, 18 & 24 months of implantation)
- Change in seizure frequency(at 3, 6, 12, 18 & 24 months of implantation.)
- Proportion of responders(at 3, 6, 12, 18 & 24 months of implantation)
- Usability(at 3, 6, 12, 18 & 24 months of implantation)
- Change in quality of life(at 3, 6, 12, 18 & 24 months of implantation)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
不适用
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery DiseaseSuperficial Femoral Artery StenosisPopliteal Artery StenosisNCT06410313Medinol Ltd.30
暂停
1 期
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid TumorsSolid TumorNCT03970382PACT Pharma, Inc.21
进行中（未招募）
1 期
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursRenal Cell CarcinomaMetastatic Colorectal CarcinomaHead and Neck Squamous Cell CarcinomaPancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerGastric CancerNon-small Cell Lung CancerNCT06147037AstraZeneca13
尚未招募
1 期
Lentiviral Gene Therapy for EpilepsyDrug Resistant EpilepsyNCT04601974University College, London10
已完成
1 期
A Phase I Study of MLN6907 in Patients With Metastatic ColorectalImaging of Solid Gastrointestinal TumorsNCT02056015Millennium Pharmaceuticals, Inc.20